Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies

Hepatology International

Volumn 9, Issue 4, 2015, Pages 586-593

  Piluso, Alessia ^a   Gragnani, Laura ^a   Fognani, Elisa ^a   Grandini, Elena ^b   Monti, Monica ^a   Stasi, Cristina ^a   Loggi, Elisabetta ^b   Margotti, Marzia ^b   Conti, Fabio ^b   Andreone, Pietro ^b   Zignego, Anna Linda ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Biomarker; Hepatitis C virus; Hepatocellular carcinoma; microRNA; Non Hodgkin s lymphoma

Indexed keywords

MICRORNA; MICRORNA 155; MICRORNA 16; MICRORNA 26B; TUMOR MARKER; UNCLASSIFIED DRUG; HEPATITIS B ANTIBODY; RNA; VIRUS DNA;

ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; AGED; BIOSYNTHESIS; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; IMMUNOLOGY; LIVER NEOPLASMS; METABOLISM; MONONUCLEAR CELL; PATHOLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS B ANTIBODIES; HEPATITIS C; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 84944513479     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9658-5     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
2. Zignego AL, Ferri C, Giannini C, La Civita L, Careccia G, Longombardo G, et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma: evidence for a pathogenetic role. Arch Virol 1997;142:545–555
3. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2009;4:399–415
4. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169–177
5. Ferri C, La Civita L, Longombardo G, Lombardini F, Pasero G, Zignego AL, et al. Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma [letter]. Clin Exp Rheumatol 1994;12:89–90
6. Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012:980942
7. Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012;7(Suppl 3):S201–S208
8. Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C virus-related mixed cryoglobulinemia: Is genetics to blame? World J Gastroenterol 2013;19:8910–8915
9. Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev 2013;23:3–11
10. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011;19:232–243
11. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013;57:840–847
12. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092–6099
13. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012;142:1431–1443
14. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647–658
15. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013;49:3442–3449
16. Peveling-Oberhag J, Crisman G, Schmidt A, Doring C, Lucioni M, Arcaini L, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012;26:1654–1662
17. Di Lisio L, Martinez N, Montes-Moreno S, Piris-Villaespesa M, Sanchez-Beato M, Piris MA. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012;120:1782–1790
18. Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, Coiffier B, et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol 2012;156:279–281
19. Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b. J Hepatol 2013;59:1362–1363
20. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189–2204
21. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437–1447
22. Fognani E, Giannini C, Piluso A, Gragnani L, Monti M, Caini P, et al. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS ONE 2013;8:e62965
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–293
24. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022
25. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361–1392
26. Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology 2012;55:1640–1642; author reply 1642–1643
27. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:355–360
28. Zeng L, Yu J, Huang T, Jia H, Dong Q, He F, et al. Differential combinatorial regulatory network analysis related to venous metastasis of hepatocellular carcinoma. BMC Genom 2012;13(Suppl. 8):S14
29. Grek M, Piekarska A, Bartkowiak J, Fendler W, Kuydowicz J, Wroblewski P, et al. Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. Int J Mol Med 2011;28:875–880
30. Zhu W, Xu B. MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis. PLoS ONE 2014;9:e103373
31. Wang Y, Gao X, Wei F, Zhang X, Yu J, et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 2014;533:389–397
32. Junker F, Chabloz A, Koch U, Radtke F. Dicer1 imparts essential survival cues in Notch driven T-ALL via miR-21 mediated tumor suppressor Pdcd4 repression. Blood 2015. doi:10.1182/blood-2014-12-61882
33. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013;52:297–303
34. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS ONE 2011;6:e26971
35. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136–142
36. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781–4788
37. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167–175
38. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672–675
39. Mao X, Sun Y, Tang J. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 2014;35:233–238
40. Minutolo A, Conti B, Grelli S, Viscomi C, Labbadia G, Balsano C. Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation. PLoS ONE 2014;9:e92343
41. Long L, Yu P, Liu Y, Wang S, Li R, Shi J, et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin Dev Immunol 2013;2013:296139
42. Gupta P, Liu B, Wu JQ, Soriano V, Vispo E, Carroll AP, et al. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. Virology 2014;450–451:336–349
43. Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci 2013;9:303–312